Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMTM in mild Alzheimer's disease
NL-OMON40577Phase 3Active, not recruiting
- Sponsor
- TauRx Therapeutics Ltd
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing LMTM 200 mg/day with Placebo twice daily (2 arms). Primary endpoints: ADAS-cog11 change from baseline, ADCS-CGIC and 2 more. Started Dec 2013; status: active, not recruiting.
02
Drugs
hydromethylthionine mesylate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON40577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40577.